GlaucomaCME

This activity is expired and is no longer available for CME credit.

ARTICLECME

Reducing IOP and Improving Compliance in 2018 New Opportunities in Medical Glaucoma Treatment

Author(s)/Faculty: John R. Samples, MD; Janet B. Serle, MD; Steven T. Simmons, MD
Release Date: 5/25/2018Expiration Date: 5/25/2019
Credit Type: CMENumber of Credits: 0
Content Type: MonographProvider:
Glaucoma is the leading cause of irreversible blindness worldwide, with an estimated 70 million people currently affected by the condition. Advances in imaging have facilitated earlier glaucoma diagnosis and subsequent timely initiation of therapy, potentially reducing irreversible blindness as well as loss of quality of life. However, many patients with glaucoma remain at risk for disease progression due to insufficient control of intraocular pressure (IOP), which may be related to inadequacy of therapy options or lack of patient adherence to treatment regimens consisting of multiple therapies. Two new therapies, which differ in their mechanisms of action from currently available therapies that only increase outflow or decrease production of aqueous humor to reduce IOP, have been recently approved by the US Food and Drug Administration. In this CME monograph, experts in the field will review and evaluate the latest clinical evidence for the safety and efficacy of current, new, and emerging classes of therapy, as well as discuss their mechanisms of action.